...my sense is that most of the Otsana clients investing in VHL are not traders, vogliobene.
It may be a tad too early to think about exit prices.
The lead shareholder, WIC, will be there for the longer term, IMO.
Dr Wayne Millen and Dr Brendan de Kauwe will be long termers and I'd suggest that de Kauwe - wearing his Otsana advisor cap - would be advising his clients to relax and be patient.
Keep in mind he's an insider.
These guys clearly represent 'smart money'.
They've trebled their outlay in three months. They may re-treble their outlay in the next three months.
This might be triggered by three events:
1. Release of an expert report on the the value/potential of the company's IP.
2. Novartis taking up its Transgene option to commercialize TG4010;
3. Announcement that funds will be sought - perhaps again from miners BHP Billiton and Rio Tinto - to progress VIR201, a proposed HIV/AIS therapeutic vaccine.
As I understand it, the FDA has issued a clearance to allow Phase 11 testing of VIR201.
VHL Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)